Literature DB >> 19759944

Synthesis and solid-state characterization of platinum complexes with hexadentate amino- and iminophosphine ligands.

Marie-Hélène Thibault1, Bryan E G Lucier, Robert W Schurko, Frédéric-Georges Fontaine.   

Abstract

Hexadentate ligands cis,cis-C(6)H(9)(N[double bond, length as m-dash]CHC(6)H(4)(PPh(2)))(3) () and cis,cis-C(6)H(9)(NHCH(2)C(6)H(4)(PPh(2)))(3) () were synthesized starting from cis,cis-1,3,5-triaminocyclohexane, and characterized using NMR spectroscopy and single-crystal X-ray diffraction. These ligands can bind both Pt(0) and Pt(II) metal centers using either or both of the soft phosphine moieties and the hard amine/imine moieties. In many cases the resulting complexes are negligibly soluble; hence, (31)P and (195)Pt solid-state NMR (SSNMR) spectroscopy was applied to analyse the bonding modes of the hexadentate ligands. The (195)Pt SSNMR spectroscopy of these complexes is particularly challenging, since (1)H-(195)Pt cross polarization is extremely inefficient, the (195)Pt longitudinal relaxation times are extremely long and the (195)Pt powder patterns are expected to be quite broad due to platinum chemical shift anisotropy. It is demonstrated that the ultra-wideline (195)Pt SSNMR spectra can be efficiently acquired with a combination of frequency-stepped piecewise acquisitions and cross-polarization/Carr-Purcell Meiboom-Gill (CP/CPMG) NMR experiments. The (195)Pt and (31)P SSNMR data are correlated to important structural features in both Pt(0) and Pt(II) species.

Entities:  

Year:  2009        PMID: 19759944     DOI: 10.1039/b907737e

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  1 in total

1.  Synthesis, spectral and solid state characterization of a new bioactive hydrazine bridged cyclic diphosphonium compound.

Authors:  Milica Milenković; Beata Warżajtis; Urszula Rychlewska; Dušanka Radanović; Katarina Anđelković; Tatjana Božić; Miroslava Vujčić; Dušan Sladić
Journal:  Molecules       Date:  2012-03-02       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.